Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC.ASMB · Entity 5216 | Director | June 05, 2025 | June 09, 2025 |
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | Director | May 21, 2025 | May 23, 2025 |
| IMMUNE DESIGN CORP.IMDZ · Entity 158527 | Director | April 02, 2019 | April 04, 2019 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | September 20, 2017 | September 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ASSEMBLY BIOSCIENCES, INC.
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.81 · Expires 2035-06-05 | Direct | 3,500 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 3,500 · Balance 3,500 F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 5, 2026 and (2) the date of the Issuer's 2026 annual meeting of stockholders.
Faeth Therapeutics, Inc.
Report date May 21, 2025 · Filed May 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2035-05-20 | Direct | 19,000 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 19,000 · Balance 19,000 F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
IMMUNE DESIGN CORP.
Report date April 02, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2: Not Applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding.
F2: Not Applicable.
SANGAMO THERAPEUTICS, INC
Report date September 20, 2017 · Filed September 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 800 |
Ending reported balance
After 2017-09-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-09-20 · Exercise / conversion · Acquired 31,000 · Balance 31,800 Row 2 · 2017-09-20 · Sale · Disposed 31,000 · Balance 800 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.55, inclusive. The Reporting Person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05 · Expires 2020-04-15 | Direct | 0 |
Reported balance
After 2017-09-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-09-20 · Exercise / conversion · Disposed 31,000 · Balance 0 F2: The shares underlying the stock option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.55, inclusive. The Reporting Person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F2: The shares underlying the stock option are fully vested and exercisable.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 24, 2020
Section 16 reporting ended · disclosed 2020-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-06-05 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Disposition to issuer · Disposed 18,275 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-20 · Disposition to issuer · Disposed 8,620 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.82 · Expires 2026-06-20 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-20 · Disposition to issuer · Disposed 10,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.01 · Expires 2027-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2029-06-03 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-20 · Disposition to issuer · Disposed 6,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-20 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
FIVE PRIME THERAPEUTICS, INC.
Report date April 05, 2021 · Filed April 19, 2021
Section 16 reporting ended · disclosed 2021-04-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-04-05 transaction · row 1
1 source rowRow 1 · 2021-04-05 · Gift · Disposed 10,000 · Balance 0 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.65 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-16 · Disposition to issuer · Disposed 16,600 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.15 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-04-16 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.80 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.27 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-04-16 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.09 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-04-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-04-16 · Disposition to issuer · Disposed 34,451 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-04-16 · Disposition to issuer · Disposed 46,939 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.23 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-04-16 · Disposition to issuer · Disposed 50,367 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-04-16 · Disposition to issuer · Disposed 49,552 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.31 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-04-16 · Disposition to issuer · Disposed 40,868 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.23 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-04-16 · Disposition to issuer · Disposed 37,998 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2021-04-16 · Disposition to issuer · Disposed 52,408 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.47 | Direct | 0 |
Reported balance
After 2021-04-16 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2021-04-16 · Disposition to issuer · Disposed 27,769 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option. F2: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated March 4, 2021 (the "Merger Agreement"), by and among the Five Prime Therapeutics, Inc. (the "Company"), Amgen Inc. ("Parent") and Franklin Acquisition Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of April 16, 2021. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each option to purchase shares of common stock of the Company, par value $0.001 per share ("Common Stock"), granted by the Company that was then outstanding and unexercised was cancelled and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of Common Stock subject to such option multiplied by (y) the excess, if any, of (A) $38.00 minus (B) the exercise price payable per share under such option.
F2: Not applicable.
PFIZER INC
Report date March 31, 2010 · Filed April 01, 2010
Section 16 reporting ended · disclosed 2010-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock Units SSPSEC Table II · derivative / convertible security | Direct | 10,415 |
Reported balance
After 2010-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2010-03-31 · Grant · Acquired 144 · Balance 10,415 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 19, 2019 Filed Oct 21, 2019 17:30 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantEmployee Stock Option (right to buy) · Derivative | 46,939 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001209191-19-053725 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,939 Underlying: Common Stock · 46,939 shares Expires 2029-10-18 F1 · derivative.exercise_date: This option will vest in its entirety on November 19, 2019, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date. Read SEC document |
| October 05, 2019 Filed Oct 8, 2019 19:30 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantEmployee Stock Option (right to buy) · Derivative | 34,451 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001209191-19-052804 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,451 Underlying: Common Stock · 34,451 shares Expires 2029-10-04 F1 · derivative.exercise_date: This option will vest in its entirety on October 19, 2019, subject to the reporting person's continued service to Five Prime Therapeutics, Inc. through such vest date. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 17:15 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003528 · primarydocument.xml · derivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F2 · derivative.exercise_date: The RSU, which was granted on June 12, 2018, fully vested on June 12, 2019. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 17:15 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003528 · primarydocument.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 18:23 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001209191-19-036508 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-09 F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) June 10, 2020 or (ii) the day before the 2020 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:15 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003406 · primarydocument.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: The RSU will vest 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:15 UTC | Dermira, Inc. DERM · Entity 11896 | GrantDirector Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $9.38 | $0.00 |
DisclosureSEC source: 0001562180-19-003406 · primarydocument.xml · derivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-06-03 F1 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date. Read SEC document |
| May 17, 2019 Filed May 17, 2019 23:37 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.22 | $0.00 |
DisclosureSEC source: 0001144204-19-027162 · tv521928_4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-17 F1 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 17, 2020 and (ii) the date of the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:10 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 12,500 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0001209191-19-023680 · doc4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:10 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 12,500 | Not disclosed Strike: $4.05 | Not disclosed |
DisclosureSEC source: 0001209191-19-023680 · doc4.xml · derivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:10 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 10,000 | Not disclosed Strike: $5.60 | Not disclosed |
DisclosureSEC source: 0001209191-19-023680 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. At the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required withholding. F2 · derivative.expiration_date: Not Applicable. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 18:07 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003458 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents shares of restricted stock, which will vest in their entirety on January 9, 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through such date. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:18 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001209191-19-002660 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-01-03 F1 · derivative.exercise_date: All shares underlying the option will vest on January 3, 2020. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 20:00 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001144204-18-037217 · v497988_4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,000 Underlying: Common Stock · 1,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 20:00 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,000 | $38.50 | $38,503.00 |
DisclosureSEC source: 0001144204-18-037217 · v497988_4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.50 to $38.515, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 20:00 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionCommon Stock | 1,000 | $7.20 | $7,200.00 |
DisclosureSEC source: 0001144204-18-037217 · v497988_4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 17:45 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003001 · primarydocument.xml · derivative · entry 4 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F5 · derivative.exercise_date: The RSU, which was granted on June 13, 2017, fully vested on June 13, 2018. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 17:45 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003001 · primarydocument.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Represents shares acquired upon vesting of RSU granted on June 13, 2017. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:45 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003001 · primarydocument.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F4 · derivative.exercise_date: The RSU will vest 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:45 UTC | Dermira, Inc. DERM · Entity 11896 | GrantDirector Stock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001562180-18-003001 · primarydocument.xml · derivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-12 F2 · derivative.exercise_date: The stock option will vest and become exercisable as to 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 21:54 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001144204-18-032476 · tv495701_4.xml · derivative · entry 4 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 1,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 21:54 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,000 | $42.47 | $42,470.00 |
DisclosureSEC source: 0001144204-18-032476 · tv495701_4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 21:54 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionCommon Stock | 1,000 | $7.20 | $7,200.00 |
DisclosureSEC source: 0001144204-18-032476 · tv495701_4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 21:54 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $42.09 | $0.00 |
DisclosureSEC source: 0001144204-18-032476 · tv495701_4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-30 F2 · derivative.exercise_date: The shares of common stock underlying the option will vest upon the earlier of (i) May 30, 2019 and (ii) the date of the Issuer's 2019 annual meeting of stockholders. Read SEC document |
| May 10, 2018 Filed May 14, 2018 20:23 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.27 | $0.00 |
DisclosureSEC source: 0001209191-18-030084 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-05-09 F1 · derivative.exercise_date: This option will vest in its entirety on the earlier to occur of (i) May 10, 2019 or (ii) the day before the 2019 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. Read SEC document |
| May 01, 2018 Filed May 2, 2018 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001144204-18-024758 · tv492751_4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 1,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016. Read SEC document |
| May 01, 2018 Filed May 2, 2018 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,000 | $43.06 | $43,060.00 |
DisclosureSEC source: 0001144204-18-024758 · tv492751_4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 01, 2018 Filed May 2, 2018 20:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionCommon Stock | 1,000 | $7.20 | $7,200.00 |
DisclosureSEC source: 0001144204-18-024758 · tv492751_4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 02, 2018 Filed Apr 2, 2018 22:07 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001144204-18-018748 · tv490129_form4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 1,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016. Read SEC document |
| April 02, 2018 Filed Apr 2, 2018 22:07 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,000 | $49.32 | $49,320.00 |
DisclosureSEC source: 0001144204-18-018748 · tv490129_form4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 02, 2018 Filed Apr 2, 2018 22:07 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionCommon Stock | 1,000 | $7.20 | $7,200.00 |
DisclosureSEC source: 0001144204-18-018748 · tv490129_form4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 21:01 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001144204-18-012524 · tv487549_4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 1,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 21:01 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,000 | $56.37 | $56,370.00 |
DisclosureSEC source: 0001144204-18-012524 · tv487549_4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 21:01 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionCommon Stock | 1,000 | $7.20 | $7,200.00 |
DisclosureSEC source: 0001144204-18-012524 · tv487549_4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 21:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001144204-18-005474 · tv484793_4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 1,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 21:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,000 | $46.86 | $46,860.00 |
DisclosureSEC source: 0001144204-18-005474 · tv484793_4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 21:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionCommon Stock | 1,000 | $7.20 | $7,200.00 |
DisclosureSEC source: 0001144204-18-005474 · tv484793_4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 20:31 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001209191-18-002817 · doc4.xml · derivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-01-04 F1 · derivative.exercise_date: All shares underlying the option will vest on January 4, 2019. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:30 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001144204-18-000532 · tv482455_4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 1,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:30 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,000 | $45.04 | $45,040.00 |
DisclosureSEC source: 0001144204-18-000532 · tv482455_4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:30 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionCommon Stock | 1,000 | $7.20 | $7,200.00 |
DisclosureSEC source: 0001144204-18-000532 · tv482455_4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001144204-17-062200 · tv480756_form4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 1,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,000 | $49.37 | $49,370.00 |
DisclosureSEC source: 0001144204-17-062200 · tv480756_form4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 01, 2017 Filed Dec 4, 2017 21:05 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionCommon Stock | 1,000 | $7.20 | $7,200.00 |
DisclosureSEC source: 0001144204-17-062200 · tv480756_form4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 14:13 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Exercise / conversionStock Option (right to buy) · Derivative | 600 | $0.00 Strike: $11.65 | $0.00 |
DisclosureSEC source: 0001209191-17-058761 · doc4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,600 Underlying: Common Stock · 600 shares Expires 2024-09-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and immediately exercisable. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 14:13 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | SaleCommon Stock | 600 | $45.33 | $27,198.00 |
DisclosureSEC source: 0001209191-17-058761 · doc4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on April 15, 2016. Read SEC document |
| November 01, 2017 Filed Nov 2, 2017 14:13 UTC | FIVE PRIME THERAPEUTICS, INC. FPRX · Entity 16595 | Exercise / conversionCommon Stock | 600 | $11.65 | $6,990.00 |
DisclosureSEC source: 0001209191-17-058761 · doc4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 21:15 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001144204-17-056293 · tv478456_4.xml · derivative · entry 3 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 1,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option, initially representing a right to purchase 64,000 shares, became exercisable in three equal installments on July 11, 2014; July 11, 2015; and July 11, 2016. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 21:15 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | SaleCommon Stock | 1,000 | $29.55 | $29,550.00 |
DisclosureSEC source: 0001144204-17-056293 · tv478456_4.xml · nonDerivative · entry 2 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,465 F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.36 to $29.75, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 21:15 UTC | ASSEMBLY BIOSCIENCES, INC. ASMB · Entity 5216 | Exercise / conversionCommon Stock | 1,000 | $7.20 | $7,200.00 |
DisclosureSEC source: 0001144204-17-056293 · tv478456_4.xml · nonDerivative · entry 1 RINGO WILLIAM R · CIK 0001238325 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The option exercise and sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.